In fact, after the outbreak of the coronavirus epidemic, Yang Jie's mind began to revolve in biopharmaceuticals, and he also asked market research companies to conduct detailed research on the domestic and foreign pharmaceutical markets.

Now, in addition to hepatitis C, international antiretroviral treatment has also made varying degrees of progress in the treatment of HIV/AIDS, and some new antiretroviral drugs have appeared, and now the mortality rate of AIDS replacement in these countries has begun to decline.

In fact, Yang Jie is interested in drugs for the treatment of asthma and chronic obstructive pulmonary disease, and there are hundreds of millions of patients suffering from these two diseases in China, and there is a huge drug market.

In addition, he values orphan drugs, that is, drugs for rare diseases, and now basically defines rare diseases as diseases with a prevalence of less than 0.002‰ or neonatal morbidity less than 0.1‰, which means that there are almost more than 20 million rare disease patients in China, and these patients have not been effectively treated at all.

At present, the investment in new drug research and development of these domestic pharmaceutical companies is very low, and there is no way to compare with those large foreign pharmaceutical companies that invest billions of dollars in R&D every year, and domestic pharmaceutical companies are in a state of disarray.

Moreover, the current R&D in China is basically in the tracking and similar structure of drugs, basically a small number of modifications have been made in the structure of similar foreign drugs, and it is very difficult to bypass foreign pharmaceutical companies.

After all, when the original manufacturers screen new drugs, they generally do a lot of derivative compound exploration around the main structure, and the probability of missing the net is very small, so even if the domestic patent is bypassed, the probability of doing better efficacy than foreign drugs is also very low.

A large number of drugs with better efficacy from these European and American pharmaceutical companies are based on the improvement of the existing structure, but they are not simply imitated and copied, and the current country is basically generic.

Yang Jie means that he wants to establish a large biopharmaceutical fund, and spend 5 billion US dollars every year to support the research and development of innovative new drugs.

As long as a sound set of pharmaceutical research and development system process is established, Yang Jie is not worried that these investments will not be recovered, as long as a successful blockbuster drug can be successful, the cost can basically be recovered, if several can be successful, there is no problem in making money.

R&D is like this, no one can guarantee that the products developed by their company will be successful, and the developed products will also be lucky, but as long as the efficacy is good, even if some drugs cannot become popular products, they can still make money.

Yang Jie said: "Drugs are a profiteering industry, the United States Pfizer is now loaded with tens of billions of dollars every year, the profit margin can reach more than 40 percent, higher than most of our subsidiaries profits, these pharmaceutical companies because of the lack of market competition, in some drugs monopolize the market, resulting in extremely expensive drug prices, we also want to join this time, make money at the same time to let the drug down." ”

He said with a smile: "The price of these drugs has always been determined by market competition, not by input costs, otherwise there will be no loss-making enterprises in this world, competition is the most powerful weapon to obtain reasonable prices, so it is very important for us to improve our technical strength in the research and development of innovative drugs." ”

"Anyway, since you are optimistic about this pharmaceutical industry, Uncle must support it. ”

Uncle said with a smile to Yang Jie.

"Yang Shao, now India is doing very well in generic drugs, if we really want to be all innovative, will the risk be too great?"

Hu Huanzhi said.

"Innovative drugs occupy more than 70% of the global drug market and are the main source of profits for the pharmaceutical industry. ”

Yang Jie said with a smile: "As long as we research and develop the drugs needed by the market, there are still very few cases of losing all our money, and we must also focus on the broader world market, we must not only actively innovate, but also actively go out." ”

Uncle nodded and said: "Huaxing Group was originally engaged in technology research and development, I think the situation of the pharmaceutical industry is very similar to our industry, it is also engaged in research and development, our Huaxing Group Company has been doing seven or eight years in the core technology, and it is still investing in these until now, if there is no person with a strategic vision like Xiaojie to do this unswervingly, there will be no Huaxing Group Company now." ”

"In the past few days, I have also been in contact with several experts in drug research and development, the research and development of new drugs is an extremely long process, the process is roughly project approval, preclinical research, CDE pending approval of clinical, clinical trials, CDE pending production, approval production transfer, a new drug to go through all the processes, how to spend seven to eight years, the risk is still very large, but now the highest risk and cost of drug research and development is the research and development and clinical trials after the drug research and development project is established. ”

"I also want to establish a large-scale third-party clinical laboratory, so that the membership cost of this association organization can be reduced, and how to share the preclinical drug research and development costs with these pharmaceutical companies also needs to make a more reasonable design plan. ”

Yang Jie nodded and said, " If the cost of these two is reduced, the risk of developing new drugs will be greatly reduced, and the willingness of domestic pharmaceutical companies to develop innovative drugs is very large, after all, leaving the cost to talk about R&D and production is a hooligan, domestic, in the past ten years, through the analysis of 106 kinds of research new drugs and biologics research and development expenses from 10 foreign companies, the successful development of a drug, the actual cost of pharmaceutical companies is 1.395 billion US dollars, plus capital time and opportunity costs, the cost of developing a new drug is 2.558 billion US dollars, and the cost of an innovative drug is close to 700 million US dollars according to our domestic cost. ”

"However, if we save the cost of clinical trials, the majority of the R&D expenses will only need six or seven billion Chinese dollars, and if we can reduce the overall cost to the level of three or four billion, we will be able to get hundreds of innovative drugs in seven or eight years, even if the success rate is only 10%, we can make a lot of money by successfully succeeding more than 10 new drugs." ”

"Another reason is that if we don't conduct research on new drug targets on innovative drugs, these foreign pharmaceutical companies will quickly consume the few feasible new drug targets left, and the cost of innovative drugs will become higher and higher in the future. ”

"Among the existing drugs, more than 50% of the drugs take the receptor as the target, and the receptor has become the most important and important target, more than 20% of the drugs take enzymes as the target, especially enzyme inhibitors, which have a special status in clinical application, about 6% of the drugs take ion channels as the target, and 3% of the drugs take nucleic acid as the target, these new drug targets have basically been studied by foreign pharmaceutical companies, and the remaining 20% The target of action of the drug needs to be further studied, and if the new drug target is not studied in China, the drug will be cut by foreign companies in the next few decades. ”

Yang Jie said: "I can't see such a thing, since no one does it, then I'll do these things myself." ”

What he wants to do is to use capital and mature operating mechanisms to stimulate the interest of domestic pharmaceutical companies in the research and development of innovative drugs and form a joint force.

At present, domestic pharmaceutical companies have a very cautious attitude towards the establishment of new drugs and the research and development of new drugs, in this mentality, many R&D are doing generic drugs, and some even generic drugs are not doing well.

Yang Jie also wants to change the impetuous atmosphere in the domestic environment, and if it takes seven or eight years to put hundreds of innovative drugs for major diseases on the market, it can bring huge benefits, and other pharmaceutical companies will naturally follow up when they see this situation, and the domestic situation will naturally change greatly.

At that time, as long as there are a number of products that can compete with foreign pharmaceutical companies, there will be competition, and those high drug prices will naturally follow, and if the drug prices come down, domestic patients can also get greater benefits.

In fact, it is very good for pharmaceutical companies to maintain their gross profits at more than 30%, which is also a normal state.